3T Biosciences

3T Biosciences

3T Biosciences is a biotechnology company developing immunotherapies.

3T Biosciences is a biotechnology company developing immunotherapies that is headquartered in Menlo Park, California and was founded in 2017 by Luke Lee, Leah Sibener, and Marvin Gee.

3T Biosciences is known for work in the T-cell therapy space. The company is utilizing machine learning to identify and predict which chemicals are found on cancer cells, but not normal ones. Then the company uses a new genetic engineering process to modify T-cells. The T-cells, which are a type of white blood cell, are used to target the cancerous chemicals. This type of therapy is currently being used to combat breast, lung, and prostate cancers. The goal of the company is to raise T-cell therapies to a new standard.

Funding

Seed

On October 4, 2017 3T Biosciences completed their seed funding round with $12 million in capital from Sean Parker (lead investor), Peter Thiel, Starlight Ventures, OS Fund, Menlo Ventures, CRV, and Asset Management Ventures (AMV).

Timeline

October 4, 2017

Seed funding round

On October 4, 2017 3T Biosciences completed their seed funding round with $12 million in capital from Sean Parker (lead investor), Peter Thiel, Starlight Ventures, OS Fund, Menlo Ventures, CRV, and Asset Management Ventures (AMV).

2017

3T Biosciences was founded by Luke Lee.

People

Name
Role
LinkedIn

Leah Sibener

Co-Founder

Luke Lee

Co-Founder, CEO

Marvin Gee

Co-Founder

Further reading

Title
Author
Link
Type
Date

Silicon Valley Billionaires are Quietly Backing This Stealth Immunotherapy Startup

Alex Keown

Web

Thiel, Parker said to fund secretive T-cell biotech startup | FierceBiotech

Ben Adams

Web

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.